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Abstract 
A critical research goal is to identify modifiable risk factors leading to functional disabilities in 
young psychiatric patients. The authors developed a multidimensional trans-diagnostic predictive 
model of functional outcome in patients with the recent-onset of a psychiatric illness. 
Baseline clinical, psychosis-risk status, cognitive, neurological-soft-signs measures, and 
dopamine-related-gene polymorphisms (DRD1-rs4532, COMT-rs165599, and DRD4-
rs1800955) were collected in 138 young non-psychotic outpatients.  
116 individuals underwent follow-up (mean=2.2 years, SD=0.9) examination.  A binary logistic 
model was used to predict low-functioning at follow-up as defined by a score lower than 65 in 
the social occupational functioning assessment scale.  
A total of 54% of patients experiences low functioning at follow-up. Attention, Avolition, and 
Motor-Coordination subscale were significant predictors of low-functioning with an accuracy of 
79.7%. A non-significant trend was found for a dopamine-related-gene polymorphism (DRD1-
rs4532). The model was independent of psychotic-risk status, DSM-diagnosis, and psychotic 
conversion.  
A trans-diagnostic approach taking into account specific neurocognitive, clinical, and 
neurological information has the potential to identify those individuals with low-functioning 
independent of DSM diagnosis or the level of psychosis-risk. 
Specific early interventions targeting modifiable risk factors and emphasize functional recovery 
in young psychiatric samples, independent of DSM-diagnosis and psychosis-risk, are essential. 
 
Key words: functioning, “neurological soft signs”, “neurocognition”, “CAARMS”, “ultra high 
risk”, “genetics” 
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1. Introduction 
 
Functional disabilities are common among mental disorders (Kessler et al., 2009). Even though 
psychotic spectrum disorders (PSDs) (Lee et al., 2015) are traditionally associated with greater 
functional disability than affective and anxiety disorders (Plaisier et al., 2010), a 2009 update 
from the World Mental Health Survey shows that severe functional impairments are not unique 
to the psychosis-spectrum (Kessler et al., 2009). A critical research goal is therefore to identify 
and intervene to target modifiable risk factors leading to long-term disability not only in PSDs, 
but in the whole spectrum of psychiatric disorders (Lee et al., 2015). 
Studies of adults with chronic mental illness show that multiple factors are linked to functional 
decline across traditional diagnostic boundaries (Iosifescu, 2012). Baseline impairments in 
functioning (Carrión et al., 2013), cognition and theory of mind (Lee et al., 2015), as well as 
neurological, neurophysiological and brain structural abnormalities (Dazzan & Murray, 2002), 
have been associated with future poor functional outcomes in schizophrenia (Chan et al., 2015), 
mood , anxiety, and personality disorders (Plaisier et al., 2010; Dazzan & Murray, 2002).  
Findings in adult populations are often tempered by chronic illness and prolonged treatment 
(Allott et al., 2011). Research efforts targeting functional recovery should thus be focused on the 
earlier phases of psychiatric disorders, when individuals are less impaired and more amenable to 
therapeutic interventions (Fusar-Poli et al., 2014). 
So far, most studies investigating functional outcome in early-onset psychiatric syndromes 
pertain to individuals with an "At-Risk Mental State" (ARMS) for psychosis (Carrión et al., 
2013). Approximately 1/3 of ARMS individuals develops a psychotic episode (Fusar-Poli et al., 
2014). However, many of them remain functionally impaired independently of psychosis 
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transition, highlighting the need for a broad, trans-diagnostic approach to functional outcome, 
cutting across the psychotic spectrum (Carrión et al., 2013).  
Given the relevance of functional outcome in psychiatry, and the evidence that disability is not 
unique to psychotic disorders (Kessler et al., 2009; Lee et al., 2015), research on early predictors 
of functional decline should target the full range of recent-onset psychiatric syndromes.  
Specifically: negative and disorganized symptoms, neurological soft signs, theory of mind, 
neurocognition, and baseline functioning abnormalities have been consistently detected in young 
psychiatric outpatients and related to future outcomes independent of DSM diagnosis and 
psychosis-risk status (Lee et al., 2015; Plaisier et al., 2010; Iosifescu, 2012; Francesconi et al., 
2016a; Minichino et al., 2016a).  These domains may represent optimal trans-categorical 
predictors of functioning and thus new promising therapeutic targets.   
Some of these domains, such as neurocognitive and theory of mind impairments, seem to be 
linked to functional disability regardless of the expression of symptoms (Francesconi et al., 
2016a; Lee  et al., 2015), as they are also expressed in the unaffected relatives of patients with 
mental illness (Tsang et al., 2015). These findings suggest that genetic factors could contribute to 
future outcome (Tsang et al., 2015) possibly as a mediating variable. Several susceptibility genes 
are associated with cellular mechanisms linked to cognitive processing domains that are 
predictors of functional outcome in ARMS studies (Plaisier et al., 2010). In particular, 
dopamine-related gene polymorphisms associated with dopaminergic function in prefrontal 
cortex, such as the Dopamine Receptor D1 (DRD1) rs4532, the Catechol-O-Methyltransferase 
(COMT) rs165599, and the Dopamine Receptor D4 (DRD4) rs1800955, have been linked to 
specific cognitive impairments (e.g. verbal fluency and working memory), in both relatives and 
patients across different diagnostic groups (Tsang et al., 2015).  
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The present study aimed to identify trans-diagnostic baseline predictors of low functional 
outcome, consistent with the Research Domain Criteria initiative from the National Institute of 
Mental Health (Cuthbert & Insel, 2013), in a large, prospective, longitudinal sample of help-
seeking adolescents and young adults treated in secondary mental health services.    
We addressed the following questions: (A) What are the functional trajectories of young patients 
with a recent-onset psychiatric disorder with 2 to 3 years of follow-up? (B) How are baseline 
functioning, cognition, theory of mind, genetic and neurological variables associated with long 
term functioning in these individuals? (C) Is prediction of functional outcome independent of (i) 
ARMS status; (ii) psychosis transition; and (iii) psychiatric diagnosis? 
 
2. Methods 
 
The institutional review board of Sapienza, University of Rome approved the study. Written 
informed consent (with assent from participants <18) was obtained from all participants. 
2.1 Participants and recruitment strategy 
Subjects were recruited in three different clinics (Rome, Italy) that provide secondary general 
mental health care for adolescents and young adults. Recruitment strategy and 
inclusion/exclusion criteria are given in eAppendix and in previously published studies 
(Francesconi et al., 2016a; Francesconi et al., 2016b; Minichino et al., 2016a).   
2.2 Baseline assessment 
Clinical information was obtained through the SCID-I and II and the Positive and Negative 
Syndrome Scale (PANSS) (Kay et al., 1987). The Comprehensive Assessment of At-Risk Mental 
States (CAARMS) interview was used to identify (Yung et al., 2005) ARMS+ and ARMS- 
individuals. The CAARMS inter-rater reliability was assessed in 34 subjects (ICC=0.93). NSS 
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were assessed with the Neurological Evaluation Scale (NES) (Buchanan & Heinrichs, 1989), 
which comprises the following subscales: “sensory-integration”, “motor-coordination”, 
“sequencing of complex motor acts”, and “others”. Neurocognition was assessed with the 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (Randolph et al. 
1998). The RBANS comprises five index scores (Attention, Immediate and Delayed Memory, 
Language and Visuospatial indices) and a total score. Social cognitive ability was assessed using 
the following scales: the Reading the Mind in the Eye Test (Baron-Cohen et al., 1997), the Faux 
Pas (Stone et al., 1998) test and the Theory of Mind Assessment Scale (Bosco et al., 2009). 
Baseline Functioning was assessed using the Global Assessment of Functioning scale (GAF) 
(Hall, 1995), the Social and Occupational Functioning Assessment Scale (SOFAS) (Yung et al., 
2005), and the Life Skills Profile-39 items (Rosen et al., 1989). The LSP-39 comprises 39 items 
grouped in 5 subscales: Self-Care, Responsibility, Communication, Non-Turbulence, and Social-
contact. A total score can be obtained by summing the responses for all items with low scores 
reflecting high level of skills. The LSP-39 total score has been consistently used as a proxy of 
real-word living skills (Puig et al., 2013). 
Genetic 
Using salivary samples, the DRD1 rs4532 (-48A/G), the COMT rs165599 and the DRD4 
rs1800955 (C-521T) polymorphisms were evaluated in a subgroup of participants (n=74) (see 
eAppendix).  
2.3 Follow-up procedure  
Functional and clinical data were collected through a single follow-up face to face interview that 
took place at a mean time of 2.2 years from the baseline assessment. Transition to psychosis was 
defined according to previously operationalized criteria (Yung et al., 2005).  
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2.4 Functional outcome 
The primary outcome variable for this study was functional outcome at the follow-up visit as 
defined by the SOFAS.  
This scale was used given its wide clinical and consistent use as primary measures of functional 
outcome in several studies and meta-analyses on ARMS individuals (Cotter et al., 2014; Fusar-
Poli et al., 2015), thus potentially facilitating interpretation of findings and future replication 
studies.  
The overall sample was divided in two groups: Low Functional (LF) and High functional (HF) 
outcome.  
LF and HF were defined as a current score of 65 and higher (HF) or 64 and lower (LF) in the 
SOFAS during the follow-up examination.  
The group split at SOFAS score of 65 was chosen according to previously published methods 
(Allen et al., 2015). The 60-70 range corresponds to the presence of “some difficulty in social or 
occupational functioning but [the subject] generally functions pretty well”. SOFAS scores below 
60 indicate “moderate to severe impairment”, whilst sores above 70 correspond to “slight 
impairment to good function”. Also, 65 was the median SOFAS value for the overall sample 
during the follow-up assessment. 
An additional measure of functional outcome, as defined by the LSP-39 total score was also 
collected at follow-up.  
2.5 Statistical analysis 
All analyses were conducted using SPSS version 21.0. Comparison of baseline characteristics 
was performed with ANOVAs for continuous variables and Pearson χ2 tests for categorical 
variables (2-tailed, P<0.05).  
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A binary logistic model was constructed to predict functional outcome according to the SOFAS-
based definition of functioning at follow-up. 
Based on previous evidence, predictor variables were generated within the following domains: 
demographic and clinical (Addington et al., 2015), neurocognitive (Meyer et al., 2014), theory of 
mind (Lee et al., 2014), NSS (Chan et al., 2009) and functioning at baseline (Carrion et al., 2013) 
(eTable1), and selected in several steps (Hosmer et al., 2013; Carrion et al., 2013) (eAppendix).  
The final models were adjusted for the possible confounding effects of (i) psychosis transition at 
follow-up; (ii) ARMS status; (iii) DSM-IV diagnosis at baseline; (iv) PANSS general subscale 
score at baseline; (v) antipsychotic and psychotherapy intervention at baseline and follow-up; 
and (vi) drug/alcohol abuse at follow-up. 
 
3. Results 
3.1 Participants  
A total of 140 participants were referred to the study. Two individuals fulfilled SCID-I criteria 
for substance abuse, and were excluded. The remaining 138 individuals underwent CAARMS 
interview. A total of 67 ARMS+ and 71 ARMS- were enrolled in the study.  
Of the 138 subjects enrolled in the study, 22 (15.9%) were lost and 116 (84.1%) completed the 
follow-up clinical evaluation, (Figure 1). Patients with follow-up information did not differ 
significantly from those lost to follow-up in any of the variables investigated. 
Table 1 shows demographic, clinical, cognitive and NSS information of the HF and LF groups.  
At baseline, the LF group had a higher prevalence of comorbid anxiety and mood disorders 
compared to the HF. Negative symptoms and functional impairments at baseline were 
significantly greater in the LF group, which was also characterized by a higher transition to 
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psychosis rate at follow-up (Table 1). Of note, the proportion of individuals who met ARMS 
criteria did not differ between the HF and LF groups.  
During the follow-up period, there was a significant difference in the percentage of change in 
functioning between the two outcome groups. Patients in the HF group showed an improvement 
in SOFAS and LSP-39 total score (+12% and +7%, respectively), while the LF group showed a 
relevant functional decline (-21% and -17%).  
At baseline, significantly lower scores on the RBANS Attention, Immediate Memory and 
Delayed Memory indices were found in LF individuals, as well as higher levels of motor- 
coordination signs (Table 1).  
3.2 Correlation among measures of functional outcome at follow-up  
Compared to the HF group, the LF group showed significantly lower scores in the follow-up 
LSP-39 total scores (Table 1).  
At follow-up, SOFAS scores were significantly correlated with LSP-39 total scores (r=-0.57: 
P=<0.001).  
3.3 Treatment 
Table 1 reports baseline and follow-up medications of the HF and LF groups. At follow-up, the 
percentage of patients in the LF group receiving antipsychotics (P<0.01), mood stabilizers 
(P<0.05) anxiolytics (P<0.05), and psychotherapy (p<0.01) was significantly higher than at 
baseline. The HF group, as well, received more antipsychotics (P<0.01) and psychotherapy 
(P<0.01) compared to baseline. These data indicate active therapeutic interventions during the 
follow-up period in both LF and HF individuals. Finally, 13.8% of the sample developed a drug 
dependence/abuse diagnosis at follow-up (P<0.01), but no differences were found between HF 
and LF.  
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3.4 Prediction of Functional outcome 
The RBANS Attention Index, the CAARMS Avolition item, and the NSS Motor-Coordination 
subscale were significant predictors of LF outcome (Table 2). The final multivariable model 
accounted for 35% of the variance (R2N=0.350) and showed a good discriminative ability, with 
an AUC of 79.7% (95% CI, 71.7-87.8; P<.001), a sensitivity of 73.0% and specificity of 67.9% 
(eFigure1).  
Prediction of functional outcome in a subgroup of individuals (n=74) with the analyzable 
genetics data 
Table 1 shows the prevalence of the DRD1 rs4532, COMT rs165599 and DRD4 rs1800955 
polymorphisms in the subgroup of patients with analyzable data (n=74). There were no 
significant differences between LF and HF groups in terms of expression of COMT rs165599 
and DRD4 rs1800955 polymorphisms. In contrast, the AG and GG genotypes of the DRD1 
rs4532 were significantly more expressed in the LF than in the HF group (P<0.05) (Table 1).  
The “presence of the G allele (DRD1)” (i.e. expression of the AG or GG genotype) was thus 
added to the set of three variables previously identified, with the aim of evaluating whether 
genetic data could improve the final predictive model of functional outcome.  
Given the smaller number of participants (n=74) available for this analysis, we decided to report 
also non-significant statistical trend results (P<0.10) for the final step of the regression.  
We used this approach, even if limited by this liberal threshold, because it could represent a 
relevant hypothesis-generating finding. Indeed: 1) there is a lack of studies investigating the 
impact of clinical-genetic interactions on prognostic outcomes in psychiatry; and 2) given the 
young age and the relatively short duration of illness characterizing our sample, our findings may 
be useful for future studies investigating early modifiable risk factors of functional disabilities.  
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Using this approach, the Attention Index, Avolition and “presence of the G allele (DRD1)” 
predicted LF with an accuracy of 81.9% (Table 3) (95% CI, 72.6-91.3; P<0.001; eFigure 2), a 
sensitivity of 75.6% and specificity of 72.7%.  The “presence of the G allele (DRD1)” entered in 
the model with a significance level of 0.058.  
The final model accounted for 39% of the variance (R2N = 0.394).  
In both the multivariable models (with and without genetic findings), the identified predictive 
variables continued to predict functional outcome even after adjusting for potential confounding 
variables (eTable2), including ARMS status, ultimate conversion status, and DSM-IV diagnosis.  
The Attention Index, Avolition and “presence of the G allele (DRD1)” were significant 
predictors of LF (Table 3). The final model accounted for 39% of the variance (R2N = 0.394). 
The overall predictive ability of this model was higher compared to the previous one, with an 
AUC of 81.9% (95% CI, 72.6-91.3; P<0.001; eFigure 2), a sensitivity of 75.6% and specificity 
of 72.7%.  In both the multivariable models, the identified predictive variables continued to 
predict functional outcome even after adjusting for potential confounding variables (eTable2), 
including ARMS status, ultimate conversion status, and DSM-IV diagnosis.  
Similar results were obtained with an alternative multivariable model built using the LSP-39 
total score as primary measure of functional outcome at follow-up (eModels). 
 
4. Discussion 
To the best of our knowledge, this is the first study using a broad trans-diagnostic approach, to 
identify predictors of functional outcome across recent onset psychiatric syndromes. Our sample 
was composed of individuals who came to a youth mental health clinic for treatment, did not 
meet criteria for a psychotic disorder and had different levels of risk for psychosis.  In contrast to 
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other ARMS samples, our participants were already diagnosed and treated for specific 
psychiatric disorders, with mean illness duration of 2.1 years, suggesting greater and more stable 
psychopathological severity. Our study yielded 4 relevant findings. First, 48% of the patients 
were ARMS+, however, low functional outcome was independent of ARMS classification and 
DSM-IV diagnosis. This confirms previous findings that baseline positive symptoms are not 
predictive of low functional outcome (Carrion et al., 2013), and suggests that categorizing 
patients based on traditional classification systems is not informative in regards to functional 
trajectories. Second, NSS, neurocognitive performance and negative symptoms at baseline were 
key predictors of LF during the early phases of different psychiatric syndromes. Third, a genetic 
marker improved the predictive model, suggesting that genetic markers may also have a relevant 
impact on functional outcome. Fourth, LF was not entirely dependent on the development of 
psychosis, further promoting the need for a broader trans-diagnostic approach in the field of 
functional recovery (Minichino et al., 2016a; Minichino et al., 2016b; Lee et al., 2015).  
Patients in the LF group showed baseline impairments on the RBANS Attention, Immediate and 
Delayed indices, with Attention being a significant predictor of functional outcome. Previous 
evidence suggests that these indices assess similar constructs as more widely used 
neurocognitive batteries (Hobart et al., 1999). Poor performance on the RBANS Attention index 
has been shown to be associated with global functioning in cohorts of chronic psychiatric 
patients independent of the diagnosis (Carrion et al., 2013). The Attention index, composed of a 
Digit span and a Coding task (Hobart et al., 1999), is a combined measure of processing speed 
and working memory (Nuechterlein et al., 2004). In a real-word context, reduced reaction time 
and an impaired ability to maintain and process information might affect global functioning, for 
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example reducing the ability to select and maintain conversational topics (Dickinson et al., 
2007).  
The LF group was also characterized by higher levels of negative symptoms, with Avolition 
being an independent predictor of functional outcome. Negative symptoms have traditionally 
been associated with schizophrenia spectrum disorders (Norman et al., 2015). However, a 
growing body of evidence suggests that they are expressed in association with LF across 
different psychiatric diagnoses (Minichino et al., 2016a). Thus, it is not surprising that Avolition 
may represent a predictor of functional outcome independent of the ARMS status and DSM-IV 
diagnosis.  
Greater motor-coordination abnormalities also made a significant independent contribution to the 
prediction of functional outcome. These results are consistent with a recent study by Mittal and 
colleagues (Mittal et al., 2014), which provides evidence for a role of NSS in predicting poor 
outcomes in ARMS individuals independent of psychosis transition. The authors also showed 
that NSS predicted a longitudinal decrease in the white matter integrity of the cerebello-thalamic 
tract that was associated with higher levels of negative symptoms. Consistent with the trans-
diagnostic approach used in the current study, high levels of NSS have been associated with 
specific neural network abnormalities, cognitive dysfunction, negative symptoms and low 
functioning in both psychotic and non-psychotic individuals (Minichino et al., 2016a; Dazzan & 
Murray, 2002).  
The expression of NSS, neurocognitive deficits, and negative symptoms can be related to 
overlapping brain structural and functional connectivity changes (Mittal et al., 2014), such as 
fronto-parietal (Chan et al., 2009) and cerebello-thalamo-prefrontal dysfunctions (Zhao et al., 
2014; Minichino et al., 2014). Consistently, the LF group showed a higher prevalence of the G 
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allele, which also showed a non-significant trend in prediction of functional outcome in a 
subgroup of patients.  
The -48A/G polymorphism is associated with a reduced binding ability of DRD1 in the 
prefrontal cortex (PFC) (Baulieu & Gainetdinov, 2011), and with a reduced PFC activation 
during cognitive tasks (Williams & Goldman-Rakic, 1992). Dysfunctions of DRD1 signaling in 
the PFC have been proposed as a potential cause of NSS (Russel et al., 2005), negative 
symptoms (Lynch, 1992) and neurocognitive deficits (Tsang et al., 2015) in both schizophrenia 
(Goldman-Rakic et al., 2004) and non-schizophrenia spectrum disorders (Tsang et al., 2015). 
Furthermore, evidence suggests that the DRD1 polymorphism may lead to antipsychotic 
resistance independent of the psychiatric diagnosis (Ota et al., 2012). It is possible that LF at 
follow-up could be associated with the expression of the G allele and thus with treatment 
resistance. This finding highlights the need for more targeted pro-cognitive intervention in 
patients with low functional trajectories. 
The reduced binding ability of the DRD1 in the PFC may trigger a cascade of events leading to 
(i) NSS abnormalities; (ii) neurocognitive impairments; (iii) greater levels of negative symptoms; 
and (iv) antipsychotics resistance, defining the common thread that characterizes those 
individuals with low functional outcome across diagnostic categories. As previously highlighted, 
motor-coordination signs, processing speed and working memory deficits, as well as severity of 
negative symptoms, have been related to shared neural vulnerabilities, mainly involving the 
cerebello-thalamo-prefrontal network (Mittal et al., 2014; Zhao et al., 2014), which is rich in 
DRD1 receptors. Young patients expressing these characteristics may benefit from specific 
interventions based on plasticity-based trainings or non-invasive brain modulation techniques 
targeting this network (Minichino et al., 2015).  These non-pharmacological strategies may be 
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particularly helpful in patients expressing the DRD1-rs4532 polymorphism, given its association 
with antipsychotics resistance.  
In conclusion, greater attention should be given to functional outcomes in patients with a recent 
onset psychiatric disorder even if they are not considered at risk for transition to psychosis. In 
secondary mental health services, a trans-diagnostic approach that takes into account specific 
neurocognitive, clinical and neurological dimensions, has the potential to identify those patients 
with a common functional trajectory, despite the clinical heterogeneity. While future studies with 
larger sample sizes are needed in order to draw definitive conclusions, our results provide useful 
information on a young psychiatric sample, in which specific therapeutic interventions have the 
potential to significantly limit functional disability.  
 
4.1 Strengths and Limitations  
Developing site-specific predictor profiles, as proposed here, has a number of limitations, the 
need for cross-validation being a primary one. Second, norms for the RBANS in children and 
adolescents are not yet available. Hence, consistent with previous evidence (Holzer et al., 2007), 
the raw scores in this study were scaled using the norms for 20–39 year olds also for all 
participants aged 17-19. Given the short administration time and its reliability, the RBANS 
represents an interesting screening tool compared to more time-consuming cognitive assessment 
batteries. Third, our ARMS+ detection rate is higher compared to those reported by previous 
studies (Rietdijk et al., 2012). However, it is still consistent with evidence suggesting that: (i) a 
consecutive screening in a secondary mental health facility detects more ARMS+ than a referral 
at suspicion strategy (54) and (ii) greater and more stable general psychopathology is associated 
with a reduction in ARMS false positives and a higher detection rate (Rietdijk et al., 2012). 
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Similarly, the rate of psychotic conversion in the identified ARMS sample (25.4%) is consistent 
with previously published rates of conversion over a 1-2.5 year time period (Cornblatt et al., 
2003). 
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TABLES 
Table 1. Demographic, clinical, genetic, cognitive and neurological soft signs variables in the 
two outcome groups (LF and HF). 
Characteristic LF (n=63) HF (N=53) P Value 
Demographic    
Age,  24.38 (3.78) 23.94 (3.47) 0.53 
 23 
mean (SD) 
Education, years,  
mean (SD) 
11.15 (3.05) 10.77 (2.78) 0.50 
Male   
N, (%) 
35 (57.4) 25 (48.1) 0.35 
Clinical 
ARMS+,  
N, (%) 
30 (47.6) 24 (45.3) 0.85 
Transition to psychosis,  
N, (%) 
16 (25.4) 5 (9.6) 0.03 
CAARMS,  
mean (SD) 
   
Positive Symptoms  7.68 (5.84) 7.11 (5.94) 0.61 
Negative Symptoms  5.79 (1.77) 4.55 (1.82) <0.001 
Emotional Disturbances  4.73 (3.14) 4.66 (3.15) 0.90 
Cognitive Change  5.00 (1.73) 4.891 (1.61) 0.72 
Behavioral Change 11.05 (2.07) 10.66 (2.16) 0.33 
PANSS,  
mean (SD) 
   
Positive Symptoms 13.16 (3.87) 13.38 (2.77) 0.74 
Negative Symptoms 14.31 (3.03) 14.50 (3.37) 0.77 
General Symptoms 37.97 (6.18) 37.77 (7.52) 0.87 
DSM-IV Diagnosis,  
N, (%) 
   
Mood Disorders a 24 (38.2) 25 (47.1) 0.32 
Anxiety Disorder b 4 (6.4) 8 (15.1) 0.12 
Personality Disorder c 10 (15.8) 10 (18.9) 0.67 
Comorbidity of Mood and Anxiety 
disordersd 
25 (39.6) 10 (18.9) 0.02 
Duration of Illness, years,  
mean (SD) 
2.16 (0.88) 2.14 (0.89) 0.87 
Baseline Medications,  
N, (%) 
   
No medications 5 (8.2) 6 (11.5) 0.75 
Antipsychotics None None  
Antidepressants 45 (73.8) 31 (59.6) 0.15 
Anxiolytics 35 (55.5) 24 (45.2) 0.27 
Mood stabilizers 16 (26.2) 10 (19.2) 0.50 
Follow up Medications,  
N, (%) 
   
No medications None 11 (20.7) <0.001 
Antipsychotics 28 (44.4) 14 (26.4) 0.04 
Antidepressants 41 (65.1) 25 (47.2) 0.06 
Anxiolytics 48 (76.2) 13 (24.5) <0.001 
Mood stabilizers 33 (52.4) 11 (20.8) <0.001 
Psychotherapy (>5 sessions),  
N (%) 
Baseline none none  
Follow up 18 (28.5) 13 (24.5) 0.62 
Baseline Functioning    
Unemployed/not in education,  
N, (%) 
30 (50.0) 23 (44.2) 0.57 
GAF,  
mean (SD) 
62.84 (9.48) 63.75 (8.49) 0.59 
 24 
SOFAS 
Mean (SD) 
64.60 (10.45) 65.00 (9.30) 0.83 
LSP-39,  
mean (SD) 
   
Self-Care 19.80 (5.98) 17.81 (4.21) 0.04 
Non turbulence 24.00 (5.53) 22.77 (5.09) 0.22 
Social Contact 11.39 (3.36) 10.62 (2.39) 0.17 
Communication 11.02 (2.89) 10.31 (2.49) 0.17 
Responsibility 10.15 (2.18) 9.44 (1.75) 0.06 
Total Score 76.36 (13.91) 70.94 (9.02) 0.02 
Follow up Functioning    
SOFAS 
 mean (SD) 
50.03 (7.1) 70.94 (6.0) <0.001 
LSP-39 Total Score 
mean (SD) 
86.84 (9.7) 74.91 (9.5) <0.001 
Genetics [N with analyzable data =74] [N= 41] [N=33]  
DRD1 rs4532 Genotype,  
N (%) 
   
AA 16 (39.1) 22 (66.7)  
AG 19 (46.3) 10 (30.3) 0.04 
GG 6 (14.6) 1 (3.0)  
Presence of the G allele,  
N (%) 
   
AG or GG 25 (60.9) 11 (33.3) 0.02 
DRD1 rs4532 Alleles frequency,  
N (%) 
   
A allele 51 (62.2) 54 (81.8) <0.001 
G allele 31 (37.8) 12 (18.2)  
DRD4 rs1800955 Genotype   
N, (%) 
   
CC 15 (36.6) 15 (45.5) 0.29 
CT 15 (36.6) 14 (42.4)  
TT 11 (26.8)  4 (12.1)  
Presence of the T allele  
N, (%) 
   
CT or TT 26 (63.4) 18 (54.5) 0.44 
DRD4 rs1800955 Alleles frequency, 
N, (%) 
   
C Allele 45 (54.8) 44 (66.7) 0.14 
T Allele 37 (45.2) 22 (33.3)  
COMT rs165599 Genotype,  
N (%) 
 
  
AA 21 (51.2) 19 (57.6) 0.18 
AG 16 (39.0) 14 (42.4)  
GG 4 (9.8) 0 (0.0)  
Presence of the G allele,  
N (%) 
   
AG or GG 20 (48.8) 14 (42.4) 0.58 
COMT rs165599 Alleles,  
N (%) 
   
A allele 58 (70.7) 52 (78.8) 0.26 
G allele 24 (29.3) 14 (21.2)  
Neurocognition    
 25 
RBANS,  
mean (SD) 
   
Immediate Memory Index 92.70 (10.15) 97.19 (9.59) 0.02 
Language Index 89.79 (8.84) 89.77 (8.55) 0.99 
Visuospatial Index 91.41 (8.90) 92.62 (8.18) 0.45 
Attention Index 80.92 (8.32) 87.42 (7.87) <0.001 
Delayed Memory Index 89.14 (8.10) 93.49 (8.24) <0.001 
Total Score 81.98 (7.93) 86.30 (8.91) <0.001 
Theory of Mind    
Faux Pas,  
mean (SD) 
   
Faux Pas questions 17.27 (1.81) 17.58 (1.43) 0.31 
Faux Pas controls 38.78 (1.15) 38.74 (1.00) 0.84 
RMET,  
mean (SD) 
25.58 (3.08) 26.02 (2.80) 0.44 
Th.o.m.as.,  
mean (SD) 
   
Thomas A 33.47 (6.63) 35.18 (5.90) 0.15 
Thomas B 28.71 (8.53) 29.08 (7.75) 0.81 
Thomas C 25.77 (7.21) 28.02 (6.46) 0.08 
Thomas D 28.32 (7.96) 28.24 (7.73) 0.95 
Neurological Soft Signs     
NES,  
mean (SD) 
   
Motor Coordination 1.97 (1.34) 1.09 (1.09) <0.001 
Sensory Integration 1.54 (1.17) 1.26 (1.02) 0.18 
Sequencing of complex motor acts 1.52 (1.45) 1.40 (1.23) 0.61 
Others 1.83 (1.61) 1.45 (1.32) 0.18 
Total Score 6.86 (4.50) 5.21 (2.90) 0.02 
 
Abbreviations: HF, High Functioning; LF, Low Functioning; ARMS+, Positive to At Risk Mental State; CAARMS, Comprehensive Assessment 
of At Risk Mental State ; PANSS, Positive And Negative Syndrome Scale; DSM- IV, Diagnostic and Statistical Manual of  Mental Disorders 4th 
Edition; GAF, Global Assessment of Functioning; LSP-39, Life Skill Profile 39 items; SOFAS, Social and Occupational Functioning Assessment 
Scale; DRD1, Dopamine Receptor D1; DRD4, Dopamine receptor D4; COMT, Catechol-O-methyltransferase; RBANS, Repeatable Battery for 
the Assessment of Neuropsychological Status; RMET, Reading the Mind Eyes in the Test; Th.o.m.a.s., Theory Of  Mind Assessment Scale; NES, 
Neurological Evaluation Scale. 
a DSM-IV diagnoses:  Major Depressive Disorder (MDD), Adjustment Disorder with Depressed Mood, Adjustment Disorder with Anxiety  
b DSM-IV diagnoses: Generalized Anxiety Disorder (GAD), Panic Disorder, Obsessive Compulsive Disorder 
c DSM-IV diagnoses:  Borderline Personality Disorder   
d DSM-IV diagnoses:  MDD and GAD,  MDD and OCD, Adjustment Disorder with Depressed Mood and Anxiety         
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Table 2. Logistic Regression Model Predicting Functional Outcome in the whole group of 
patients (n=116) 
Predictor 
Variable 
β SE 
Wald 
X2 
Hazard 
Ratio 
P Value 
AUCa (SE) 
[95% CI] 
R2N Sensitivity Specificity 
Attention 
(RBANS) 
0.079 0.03 8.34 1.08 0.004 
    
Motor -0.547 0.21 6.79 0.57 0.009 0.797 (0.041) 0.350 0.730 0.679 
 27 
Coordination 
(NES) 
[0.717-0.878] 
Avolition 
(CAARMS) 
-0.744 0.26 8.02 0.47 0.005 
    
 
Abbreviations: RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; NES, Neurological Evaluation Scale; CAARMS, 
Comprehensive Assessment of At Risk Mental State; AUC, Area Under the Curve; R2N, Nagelkerke pseudo R2 statistic; SE, Standard Error. 
 
a The AUC values can range from 0.5 (indicates that an instrument can discriminate between groups no better than chance) to 1.0 (represents 
perfect discriminatory performance) and can be interpreted using the following categories: acceptable = 0.70, good = 0.80, and excellent = 0.90. 
 
 
Table 3. Logistic Regression Model Predicting Functional Outcome in a subgroup of patients 
(n=74) with genetic available data 
 
Predictor 
Variable 
β SE 
Wald 
X2 
Hazard 
Ratio 
P Value 
AUCa (SE) 
[95% CI] 
R2N Sensitivity Specificity 
Attention 
(RBANS) 
0.078 0.03 5.11 1.08 0.024     
Presence of the 
G allele 
(DRD1) 
-1.085 0.57 3.60 0.34 0.058 
0.819 (0.048) 
[0.726-0.913] 
0.394 0.756 0.727 
Avolition 
(CAARMS) 
-0.946 0.35 7.14 0.38 0.008     
 
Abbreviations: RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; DRD1, Dopamine Receptor D1; CAARMS, 
Comprehensive Assessment of At Risk Mental State. AUC, Area Under the Curve; R2N, Nagelkerke pseudo R2 statistic; SE, Standard Error. 
a The AUC values can range from 0.5 (indicates that an instrument can discriminate between groups no better than chance) to 1.0 (represents 
perfect discriminatory performance) and can be interpreted using the following categories: acceptable = 0.70, good = 0.80, and excellent = 0.90. 
 
 
 
 
 
 
 
Figure Legend 
Figure 1. Flow chart showing the different phases of the recruitment strategy and the follow-up at a mean 
time of 2.2 years. 
Abbreviation: SCID-I and II: Structured clinical interview for DSM-IV Axis I and II disorders 
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